Research programme: USP37/USP47 inhibitors - MISSION Therapeutics
Latest Information Update: 15 Jan 2024
At a glance
- Originator MISSION Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action USP37 protein inhibitors; USP47 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 17 Oct 2023 Research programme: USP37/USP47 targeting therapeutics - MISSION Therapeutics is available for licensing as of 17 Oct 2023. https://missiontherapeutics.com/partnering/
- 17 Oct 2023 Early research in Cancer in United Kingdom (unspecified route) (Prior to October 2023) (MISSION Therapeutics Pipeline, October 2023)